Results 101 to 110 of about 5,674 (178)

Biochemical and Demographic Factors Affecting Antiviral Treatment Failure in Hepatitis C Patients with Persistent Virologic Response Issues

Pakistan Journal of Medical Research
Background: Worldwide, Hepatitis C virus (HCV) infection is a major public health concern. Twelve weeks following treatment completion, the persistent virologic response is known as SVR.
Sundus Bukhari, Mutayyaba Majeed, Maria Liaqat, Sana Shakeel, Maria Muddassir, Faheem Hadi, Tahir Maqbool   +6 more
doaj  

Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures. [PDF]

AMB Express
Abd Elsalam MA, Kutkat O, Moatasim Y, Mostafa A, Gaballah M, Elgendy AE, Ali MA, Hadad G, Shabayek S.   +8 more
europepmc   +1 more source

Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. [PDF]

J Viral Hepat
Suoh M, Esmaili S, Eslam M, George J.
europepmc   +1 more source

Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. [PDF]

J Med Virol
Hirata S, Nogami E, Udono T, Fujisawa M, Tanaka Y.   +4 more
europepmc   +1 more source

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report. [PDF]

Ann Med Surg (Lond)
Sajjad W, Rehman UU, Inam A, Alam I, Ghafoor S, Razzaq HD, Khwajakhail T, Gillani SHMUD, Razzaq H, Qamar I, Ali R, Ullah Z.   +11 more
europepmc   +1 more source

Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment. [PDF]

J Infect Dis
Goyal A, Cotler SJ, Matthews GV, Page K, Kushner T, Etzion O, Martinello M, Dahari H.   +7 more
europepmc   +1 more source

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Keshavarz K, Teymourzadeh E, Abyazi MA, Alavian SM, Pouria A.   +6 more
europepmc   +1 more source

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source

A G-Quadruplex-Activated Near-Infrared Chemiluminescent Probe for In Situ Hepatic Imaging of the Hepatitis C Virus Genome. [PDF]

Angew Chem Int Ed Engl
Li W, Du S, Li Z, Wang J, Li H, Zhu H, Kuang S, Nie Z.   +7 more
europepmc   +1 more source